Device and drug for treating tinea pedis

Abstract

The invention discloses a device and drug for treating tinea pedis. The device for treating the tinea pedis is used for partitioning the skin between the adjacent toes to make the tinea pedis infectedpart exposed in air, and the living environment of anaerobic fungi is destroyed; the drug for treating the tinea pedis is an oxygen slow-release agent, the oxygen slow-release agent reacts with waterto emit oxygen and meanwhile makes local air dry, the anaerobic fungi exposed in the air are placed in the dry environment with sufficient oxygen, and therefore the effect of treating the tinea pedisis achieved.

Description

technical field [0001] The invention relates to the related field of beriberi treatment, in particular to a device and medicine for treating beriberi. Background technique [0002] The cause of athlete's foot is that the skin between the toes is rich in sweat glands and sweats more. Moreover, the skin between the toes is close together, the air circulation is poor, and the local area is humid and warm, which is suitable for the growth of anaerobic fungi and easily forms athlete's foot (tinea pedis). In order to solve the problem of beriberi, the invention patents with application numbers "201510366275.1", "201110055280.2", "201610085404.4", "201810004674.7" proposed their own solutions, but these solutions have the following problems: [0003] 1. There is no long-term control of the humidity of the foot environment. The invention patents with application numbers "201510366275.1", "201110055280.2", and "201610085404.4" did not take into account the poor air circulation of th...

AI Technical Summary

Problems solved by technology

[0003] 1. There is no long-term control of the humidity of the foot environment. The invention patents with application numbers "201510366275.1", "201110055280.2", and "201610085404.4" did not take into account the poor air circulation of the feet when wearing shoes. When the humidity increases after hair loss, after the humidity increases, the sweat on the skin surface cannot evaporate in time, and a layer of sweat liquid film is formed on the skin surface of the toes, which hinders the contact between the skin and the air, and prevents anaerobic fungi from contacting the bacteria containing bacteria. Oxygen air creates favorable conditions for the growth of anaerobic fungi, thereby promoting the occurrence of athlete's foot

[0004] 2. The oxygen concentration in the local environment of the toes is not controlled. The invention patents with application numbers "201510366275.1", "201110055280.2", "201610085404.4", and "201810004674.7" do not take into account that the oxygen concentration in the local environment of the toes will be affected by the skin surface The role of aerobic bacteria in the toes is reduced, and the oxygen concentration in the local environment of the toes is reduced to provide good conditions for the growth of anaerobic fungi, thereby promoting the occurrence of athlete's foot

The U.S. DNA approved the use of zinc oxide in 1999, but believed that nano-zinc oxide had safety problems and did not allow its use. In 2006, it approved nano-zinc oxide as a new active ingredient.

[0006] 4. The invention patents with application numbers "201510366275.1", "201110055280.2", "201610085404.4", "201810004674.7" did not consider the situation of athlete's foot in a certain toe, but for all toes. Isolation, which is different from the original environment of the user's toes, will rub against the skin and cause discomfort. If the toes have athlete's foot, the discomfort caused by treatment can be overcome, but if a certain toe does not have athlete's foot and it is necessary to endure this discomfort will be Cause complaints from users, not conducive to the promotion of patented products, but also cause unnecessary troubles to users

[0007] 5. The invention patents with application numbers "201510366275.1", "201110055280.2", "201610085404.4", "201810004674.7" did not consider that athlete's foot spread from the root of the toes. These patents only considered the separation of the toes, and the products did not According to individual user customization, the skin at the base of the toe may not be separated, and the treatment effect for this situation cannot satisfy the user

[0008] 6. The invention patents with the application numbers "201510366275.1", "201110055280.2", "201610085404.4", "201810004674.7" did not consider customization according to the arrangement of the user's toes. The user's foot shape is ever-changing, which will make the user's toes and The fit of the above-mentioned patented product cannot be complete, which will cause the friction between the toes and the above-mentioned patented product, causing discomfort to the user, and the comfort cannot be guaranteed. If the friction part is the ulcerated part of the athlete's foot, the degree of ulceration of the ulcerated part of the athlete's foot will be aggravated. If the athlete's foot is not cured In some cases, it aggravates the degree of ulceration of beriberi

[0009] 7. The invention patents with application numbers "201510366275.1", "201110055280.2", "201610085404.4", "201810004674.7" did not consider customization according to the arrangement of the user's toes. Due to the ever-changing user's foot shape, some users' feet unusable, very poor applicability

[0010] In summary, there are various problems in the treatment of beriberi in the existing invention patents, which cannot achieve the desired effect and are very poor in practicability

Images